NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî àëëåðãîëîãèè è èììóíîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Bousfiha A, Jeddane L, Al-Herz W, et al: The 2015 IUIS phenotypic classification for primary immunodeficiencies, J Clin Immunol 35:727–738, 2015.
Chinen J, Notarangelo LD, Shearer WT: Advances in basic and clinical immunology in 2014, J Allergy Clin Immunol 135:1132–1141, 2015.
Costa-Carvalho BT, Grumach AS, Franco JL, et al: Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice, J Clin Immunol 34:10–22, 2014.
Kwan A, Abraham RS, Currier R, et al: Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States, JAMA 312:729–738, 2014.
Pai SY, Logan BR, Griffith LM, et al: Transplantation outcomes for severe combined immunodeficiency, 2000–2009, N Engl J Med 371:434–446, 2014.
Picard C, Al-Herz W, Bousfiha A, et al: Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015, J Clin Immunol 35:696–726, 2015.
Hoffman W, Lakkis FG, Chalasani G: B cells, antibodies, and more, Clin J Am Soc Nephrol 11(1):137–154, 2016.
Takahama Y: Journey through the thymus: stromal guides for T-cell development and selection, Nat Rev Immunol 6(2):127–135, 2006.
Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ: Mechanisms of Jak/STAT signalling in immunity and disease, J Immunol 194(1):21–27, 2015.
Cuccherini B, Chua K, Gill V, et al: Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to flexispiral heliocobacter species, Clin Immunol 97(2):121–129, 2000.
Gathmann B, Mahlaoui N, Gerard L, et al: Clinical picture and treatment of 2212 patients with common variable immunodeficiency, J Allergy Clin Immunol 134:116–126, 2014.
Jacobs ZD, Guajardo JR, Anderson KM: XLA-associated neutropenia treatment: a case report and review of the literature, J Pediatr Hematol Oncol 30(8):631–634, 2008.
Leven EA, Maffucci P, Ochs HD, et al: Hyper IgM syndrome: a report from the USIDNET registry, J Clin Immunol 36:490–501, 2016.
Maffucci P, Filion CA, Boisson B, et al: Genetic diagnosis using whole exome sequencing in common variable immunodeficiency, Front Immunol 7:220, 2016.
The Medical Letter: A new subcutaneous immune globulin (HyQvia) for primary immunodeficiency, Med Lett Drugs Ther 57(1476):121–122, 2015.
Oksenhendler E, G?rard L, Fieschi C, et al: Infections in 252 patients with common variable immunodeficiency, Clin Infect Dis 46:1547–1554, 2008.
Preece K, Lear G: X-linked agammaglobulinemia with normal immunoglobulin and near-normal vaccine seroconversion, Pediatrics 136(6):e1621–e1624, 2015.
Qamar N, Fuleihan RL: The hyper IgM syndromes, Clin Rev Allergy Immunol 46: 120–130, 2014.
Ravell J, Chaigne-Delalande B, Lenardo M: X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect, Curr Opin Pediatr 26:713–719, 2014.
Resnick ES, Moshier EL, Godbold JH, et al: Morbidity and mortality in common variable immune deficiency over 4 decades, Blood 119:1650–1657, 2012.
Rezaei N, Mahmoudi E, Aghamohamadi A, et al: X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma, Br J Haematol 152:13–30, 2010.
Tabolli S, Giannantoni P, Pulvirenti F, et al: Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies, Front Immunol 5:605, 2014.
Bonilla FA: Intravenous and subcutaneous immunoglobulin G replacement therapy, Allergy Asthma Proc 37(6):426–431, 2016.
Sriaroon P, Ballow M: Immunoglobulin replacement therapy for primary immuno-deficiency, Immunol Allergy Clin North Am 35(4):713–730, 2015.
Bayer DK, Martinez CA, Sorte HS, et al: Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray, Clin Exper Immunol 178:459–469, 2014.
Bousfiha A, Jeddane L, Al-Herz W, et al: The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies, J Clin Immunol 35(8):727–738, 2015.
Husebye ES, Perheentupa J, Rautemaa R, Kampe O: Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type 1, J Intern Med 265:514–529, 2009.
Kisand K, Peterson P: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome, Ann NY Acad Sci 1246:77–91, 2011.
Morsheimer M, Brown Whitehorn TF, Heimall J, Sullivan KE: The immune deficiency of chromosome 22q11.2 deletion syndrome, Am J Med Genet A 173(9):2366–2372, 2017.
Notarangelo LD: Combined immunodeficiencies with nonfunctional T lymphocytes, Adv Immunol 121:121–190, 2014.
O’Shea JJ, Holland SM, Staudt LM: JAKs and STATs in immunity, immunodeficiency, and cancer, N Engl J Med 368:161–168, 2013.
Patel K, Akhter J, Kobrynski L, et al: Immunoglobulin deficiencies: the B-lymphocyte side of DiGeorge syndrome, J Pediatr 161:950–953, 2012.
Picard C, Al-Herz W, Bousfiha A, et al: Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015, J Clin Immunol 35(8):696–726, 2015.
Reichenbach J, Schubert R, Horvath R, et al: Fatal neonatal-onset mitochondrial respiratory chain disease with T-cell immunodeficiency, Pediatr Res 60(3):321–326, 2006.
Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA . 2014;312:729–738.
Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med . 2014;371:434–446.
Akdis CA: Therapies for allergic inflammation: refining strategies to induce tolerance, Nat Med 18:736–749, 2012.
Akdis M, Aab A, Altunbulakli C, et al: Interleukins (from IL-1 to IL-38), interferons, transforming growth factor |3, and TNF-a: receptors, functions, and roles in diseases, J Allergy Clin Immunol 138(4):984–1010, 2016.
Bachert C, Akdis CA: Phenotypes and emerging endotypes of chronic rhinosinusitis, J Allergy Clin Immunol Pract 4(4):621–628, 2016.
Boyce JA, Bochner B, Finkelman FD, et al: Advances in mechanisms of asthma, allergy, and immunology in 2011, J Allergy Clin Immunol 129:335–341, 2012.
Busse WW, Morgan WJ, Taggart V, et al: Asthma outcomes workshop: overview, J Allergy Clin Immunol 129: S1–S8, 2012.
Holgate ST: Innate and adaptive immune responses in asthma, Nat Med 18:673–683, 2012.
Kucuksezer UC, Palomares O, Ruckert B, et al: Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood, J Allergy Clin Immunol 131:875–885, 2013.
Kuo IH, Yoshida T, De Benedetto A, et al: The cutaneous innate immune response in patients with atopic dermatitis, J Allergy Clin Immunol 131:266–278, 2013.
Liu AH, Anderson WC 3rd, Dutmer CM, et al: Advances in asthma 2015: across the lifespan, J Allergy Clin Immunol 138(2):397–404, 2016.
Morita H, Moro K, Koyasu S: Innate lymphoid cells in allergic and nonallergic inflammation, J Allergy Clin Immunol 138(5):1253–1264, 2016.
Palomares O, Ruckert B, Jartti T, et al: Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance, J Allergy Clin Immunol 129:510–520, 2012.
Ross LE, Grigoroadis S, Mamisashvili L, et al: Selected pregnancy and delivery outcomes after exposure to antidepressant medication, JAMA Psychiatry 70(4):436–443, 2013.
Sicherer SH, Leung DY: Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012, J Allergy Clin Immunol 131:55–66, 2013.
Tang TS, Bieber T, Williams HC: Does “autoreactivity” play a role in atopic dermatitis?, J Allergy Clin Immunol 129:1209–1215, 2012.
Vandre Veen W, Stanic B, Yaman G, et al: IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses, J Allergy Clin Immunol 131:1204–1212, 2013.
Vercelli D: Remembrance of things past: HLA genes come back on the allergy stage, J Allergy Clin Immunol 129:846–847, 2012.
Wawrzyniak P, Akdis CA, Finkelman FD, Rothenberg ME: Advances and highlights in mechanisms of allergic disease in 2015, J Allergy Clin Immunol 137(6):1681–1696, 2016.
Zabielinski M, McLeod MP, Aber C, et al: Trends and antibiotic susceptibility patterns of methicillin-resistant and methicillin-sensitive Staphylococcus aureus in an outpatient dermatology facility, JAMA Dermatol 149(4):427–432, 2013.
Adkinson NF Jr, Bochner BS, Burks AW, et al, editors: Middleton's allergy: principles & practice, ed 7, Philadelphia, 2014, Elsevier/Saunders.
Galli SJ: Toward precision medicine and health: opportunities and challenges in allergic diseases, J Allergy Clin Immunol 137(5):1289–1300, 2016.
Hamilton RG, Oppenheimer J: Serological IgE analyses in the diagnostic algorithm for allergic disease, J Allergy Clin Immunol Pract 3(6):833–840, quiz 841–842, 2015.
Hirano I: 2015 David Y. Graham Lecture: The first two decades of eosinophilic esophagitis — from acid reflux to food allergy, Am J Gastroenterol 111(6):770–776, 2016.
Miraldi Utz V, Kaufman AR: Allergic eye disease, Pediatr Clin North Am 61(3):607–620, 2014.
Scadding GK, Scadding GW: Diagnosing allergic rhinitis, Immunol Allergy Clin North Am 36(2):249–260, 2016.
Stukus DR, Mikhail I: Pearls and pitfalls in diagnosing IgE-mediated food allergy, Curr Allergy Asthma Rep 16(5):34, 2016.
Wood RA: Advances in food allergy in 2015, J Allergy Clin Immunol 138(6):1541–1547, 2016.
Zellweger F, Eggel A: IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment, Allergy 71(12):1652–1661, 2016.
Barnes PJ: Pathophysiology of allergic inflammation, Immunol Rev 242:31–50, 2011.
Burks AW, Calderon MA, Casale T, et al: Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report, J Allergy Clin Immunol 131:1288–1296, 2013.
Calderon MA, Gerth van Wijk R, Eichler I, et al: Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement, Pediatr Allergy Immunol 23:300–306, 2012.
Codispoti CD, Bernstein DI, Levin L, et al: Early-life mold and tree sensitivity is associated with allergic eosinophilic rhinitis at 4 yr of age, Ann Allergy Asthma Immunol 114:193–198 e4, 2015.
Cox LS: Sublingual immunotherapy for allergic rhinitis — is 2-year treatment sufficient for long-term benefit? JAMA 317(6):591–593, 2017.
Garcia-Aymerich J, Benet M, Saeys Y, et al: Phenotyping asthma, rhinitis and eczema in MeDALL population-based birth cohorts: an allergic comorbidity cluster, Allergy 70:973–984, 2015.
Howarth PH, Mygind N, Silkoff PE, et al: Preface to outcome measures in allergic rhinitis, J Allergy Clin Immunol 115: S387–S389, 2005.
Kim JM, Lin SY, Suarez-Cuervo C, et al: Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review, Pediatrics 131(6):1155–1167, 2013.
La Rosa M, Lionetti E, Reibaldi M, et al: Allergic conjunctivitis: a comprehensive review of the literature, Ital J Pediatr 39:18, 2013.
Lin SY, Erekosima N, Kim JM, et al: Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review, JAMA 309:1278–1288, 2013.
The Medical Letter: Allergic rhinitis, Med Lett Drugs Ther 59:71–80, 2017.
Nwaru BI, Takkinen HM, Niemela O, et al: Timing of infant feeding in relation to childhood asthma and allergic diseases, J Allergy Clin Immunol 131:78–86, 2013.
Patil VK, Kurukulaaratchy RJ, Venter C, et al: Changing prevalence of wheeze, rhinitis and allergic sensitisation in late childhood: findings from 2 Isle of Wight birth cohorts 12 yr apart, Clin Exp Allergy 45:1430–1438, 2015.
Roberts G, Xatzipsalti M, Borrego LM, et al: Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology, Allergy 68:1102–1116, 2013.
Scadding GK, Durham SR, Mirakian R, et al: BASCI guidelines for the management of allergic and non-allergic rhinitis, Clin Exp Allergy 38:19–42, 2008.
Schmitt J, Schwarz K, Stadler E, et al: Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study, J Allergy Clin Immunol 136:1511–1516, 2015.
Valenta R, Campana R, Focke-Tejkl M, et al: Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future, J Allergy Clin Immunol 137:351–357, 2016.
Westman M, Lupinek C, Bousquet J, et al: Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence, J Allergy Clin Immunol 135:1199–1206 e1–e11, 2015.
Wheatly LM, Togias A: Allergic rhinitis, N Engl J Med 372(15):456–462, 2015.
Bacharier LB: Reducing exposure to mouse allergen among children and adolescents with asthma is achievable, but is it enough? JAMA 317(10):1023–1024, 2017.
Cahill KN, Katz HR, Cui J, et al: KIT inhibition by imatinib in patients with severe refractory asthma, N Engl J Med 376(20):1911–1920, 2017.
Chung KF: Dupilumab: a potential new treatment for severe asthma, Lancet 388:3–4, 2016.
Chung KF: Targeting the interleukin pathway in the treatment of asthma, Lancet 386:1086–1094, 2015.
Cronin JJ, McCoy S, Kennedy U, et al: A randomized trial of single-dose oral dexamethasone versus multidose prednisolone for acute exacerbations of asthma in children who attend the emergency department, Ann Intern Med 67(5):593–601, 2016.
Dinakar C, Chipps BE: Clinical tools to assess asthma control in children, Pediatrics 139:57–65, 2017.
Dodda VR, Spiro P: Can albuterol be blamed for lactic acidosis? Respir Care 57(12): 2115–2118, 2012.
Ebmeier S, Thayabaran D, Braithwaite I, et al: Trends in international asthma mortality: analysis of data from the WHO mortality database from 46 countries (1993–2012), Lancet 390:935–944, 2017.
FitzGerald JM, Emery P: Modifying the trajectory of asthma: are there lessons from the use of biologics in rheumatology? Lancet 389:1082–1084, 2017.
Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention, 2016. www.ginasthma.org.
Israel E, Reddel HK: Severe and difficult-to-treat asthma in adults, N Engl J Med 377(10):965–976, 2017.
Keeney GE, Gray MP, Morrison AK, et al: Dexamethasone for acute asthma exacerbations in children: a meta-analysis, Pediatrics 133(3):493–499, 2014.
Kelly HW, Sternberg AL, Lescher R, et al: Effect of inhaled glucocorticoids in childhood on adult height, N Engl J Med 367:904–912, 2012.
Kim JM, Lin SY, Suarez-Cuervo C, et al: Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review, Pediatrics 131(6):1155–1167, 2013.
Lemanske RF Jr, Mauger DT, Sorkness CA, et al: Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids, N Engl J Med 362:975–985, 2010.
Liu AH, Babineau DC, Krouse RZ, et al: Pathways through which asthma risk factors contribute to asthma severity in inner-city children, J Allergy Clin Immunol 138: 1042–1050, 2016.
Liu AH, Martinez FD: Natural history of allergic diseases and asthma. In Leung DYM, editor: Pediatric allergy: principles & practice, ed 3, Philadelphia, 2015, Elsevier.
Matsui EC, Abramson SL, Sandel MT: Indoor environmental control practices and asthma management, Pediatrics 138(5):2016.
McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ: Diagnosis and management of asthma in adults: a review, JAMA 318(3):279–290, 2017.
The Medical Letter: Drugs for asthma, Med Lett 59(1528):139–146, 2017.
The Medical Letter: Mepolizumab (Nucala) for severe eosinophilic asthma, Med Lett 58(1486):11–12, 2016.
The Medical Letter: Reslizumab (Cinqair) for severe eosinophilic asthma, Med Lett 58(1497):81–82, 2016.
McGeachie MJ, Yates KP, Zhou X, et al: Patterns of growth and decline in lung function in persistent childhood asthma, N Engl J Med 374:1842–1852, 2016.
Nair P, Wenzel S, Rabe KF, et al: Oral glucocorticoid-sparing effect of benralizumab in severe asthma, N Engl J Med 376(25):2448–2458, 2017.
National Asthma Education and Prevention Program Expert Panel Report 3 (EPR3): Guidelines for the diagnosis and management of asthma, NIH Pub No 07-4051, Bethesda, MD, 2007, US Department of Health and Human Services; National Institutes of Health, National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program.
Newth CJL, Meert KL, Clark AE, et al: Fatal and near-fatal asthma in children: the critical care perspective, J Pediatr 161:214–221, 2012.
Paniagua N, Lopez R, Munoz N, et al: Randomized trial of dexamethasone versus prednisone for children with acute asthma exacerbations, J Pediatr 191:190–196, 2017.
Parikh K, Hall M, Mittal V, et al: comparative effectiveness of dexamethasone versus prednisone in children hospitalized with asthma, J Pediatr 167:639–644, 2015.
Pongracic JA, Krouse RZ, Babineau DC, et al: Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents, J Allergy Clin Immunol 138:1030–1041, 2016.
Rehrer MW, Liu B, Rodriguez M, et al: A randomized controlled noninferiority trial of single dose of oral dexamethasone versus 5 days of oral prednisone in acute adult asthma, Ann Emerg Med 68(5):608–613, 2016.
Sheehan WJ, Mauger DT, Moy PJN, et al: Acetaminophen versus ibuprofen in young children with mild persistent asthma, N Engl J Med 375(7):619–630, 2016.
Stempel DA, Szefler SJ, Pedersen S, et al: Safety of adding salmeterol to fluticasone propionate in children with asthma, N Engl J Med 375:840–849, 2016.
Spahn JD, Malka J, Szefler SJ: Current application of exhaled nitric oxide in clinical practice, J Allergy Clin Immunol 138:1296–1298, 2016.
Teach SJ, Gill MA, Togias A, et al: Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations, J Allergy Clin Immunol 136:1476–1485, 2015.
Zoratti EM, Krouse RZ, Babineau DC, et al: Asthma phenotypes in inner-city children, J Allergy Clin Immunol 138:1016–1029, 2016.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AS CHRONOS): a 1-year randomized, double-blind, placebo-controlled, phase 3 trial, Lancet 389:2287-2303, 2017.
Boguniewicz M, Leung DY: The ABC's of managing patients with severe atopic dermatitis, J Allergy Clin Immunol 132(2):511-512, 2013.
Cole C, Kroboth K, Schurch NJ, et al: Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis, J Allergy Clin Immunol 134:82-91, 2014.
Eichenfield LF, Tom WL, Chamlin SL, et al: Guidelines of care for the management of atopic dermatitis. Section 1. Diagnosis and assessment of atopic dermatitis, J Am Acad Dermatol 70(2):338-351, 2014.
Eichenfield LF, Tom WL, Berger TG, et al: Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies, J Am Acad Dermatol 71(1):116-132, 2014.
Esaki H, Brunner PM, Renert-Yuval Y, et al: Early-onset pediatric atopic dermatitis is TH2, but also TH17 polarized in skin, J Allergy Clin Immunol 138(6):1639-1651, 2016.
Francis NA, Ridd MJ, Thomas-Jones E, et al: Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care, Ann Fam Med 15(2):124-130, 2017.
Horimukai K, Morita K, Narita M, et al: Application of moisturizer to neonates prevents development of atopic dermatitis, J Allergy Clin Immunol 134:824-830, 2014.
Irvine AD, McLean WHI, Leung DYM: Filaggrin mutations associated with skin and allergic diseases, N Engl J Med 365:1315-1327, 2011.
Kim J, Kim BE, Lee J, et al: Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy, J Allergy Clin Immunol 137(4): 1282-1285, 2016.
Kong HH, Oh J, Deming C, et al: Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis, Genome Res 22:850-859, 2012.
Leung DY: Clinical implications of new mechanistic insights into atopic dermatitis, Curr Opin Pediatr 28(4):456-462, 2016.
Leung DYM, Guttman-Yassky E: Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches, J Allergy Clin Immunol 134:769-779, 2014.
The Medical Letter: Dupilumab (Dupixent) for moderate to severe atopic dermatitis, Med Lett Drugs Ther 59(1519):64-66, 2017.
The Medical Letter: Crisaborole (Eucrisa) for atopic dermatitis, Med Lett Drugs Ther 59(1515):34, 2017.
The Medical Letter: Allergic rhinitis, Med Lett Drugs Ther 59(1520):71-80, 2017.
Ruzicka T, Hanifin JM, Furue M, et al: Anti-interleukin-31 receptor A antibody for atopic dermatitis, N Engl J Med 376(9):826-835, 2017.
Schneider L, Lio P, Boguniewicz M, et al: Atopic dermatitis: a practice parameter update 2012, J Allergy Clin Immunol 131:295-299, 2013.
Shaw TE, Currie GP, Koudelka CW, et al: Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health, J Invest Dermatol 131:67-73, 2011.
Sidbury R, Davis DM, Cohen DE, et al: American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents, J Am Acad Dermatol 71(2):327-349, 2014.
Sidbury R, Tom WL, Bergman JN, et al: Guidelines of care for the management of atopic dermatitis. Section 4. Prevention of disease flares and use of adjunctive therapies and approaches, J Am Acad Dermatol 71(6):1218-1233, 2014.
Sigurgeirsson B, Boznanski A, Todd G, et al: Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial, Pediatrics 135(4):598-606, 2015.
Shi B, Bangayan NJ, Curd E, et al: The skin microbiome is different in pediatric versus adult atopic dermatitis, J Allergy Clin Immunol 138:1233-1236, 2016.
Simpson EL, Bieber T, Guttman-Yassky E, et al: Two phase 3 trials of dupilumab versus placebo in atopic dermatitis, N Engl J Med 375(24):2335-2348, 2016.
Simpson EL, Chalmers JR, Hanifin JM, et al: Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention, J Allergy Clin Immunol 134:818-823, 2014.
Stein SL, Cifu AS: Management of atopic dermatitis, JAMA 315(14):1510-1511, 2016. Thaci D, Simpson EL, Beck LA, et al: Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial, Lancet 387:40-52, 2016.
Togias A, Cooper SF, Acebal ML, et al: Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel, J Allergy Clin Immunol 139:29-44, 2017.
Werfel T, Allam JP, Biedermann T, et al: Cellular and molecular immunologic mechanisms in patients with atopic dermatitis, J Allergy Clin Immunol 138:336-349, 2016.
Bild MB, Cichocka-Jarosz E, Pumphrey R, et al: Self-medication of anaphylactic reactions due to Hymenoptera stings: an EAACI task force consensus statement, Allergy 71(7):931-943, 2016.
Casale TB, Burks AW: Clinical practice. Hymenoptera-sting hypersensitivity, N Engl J Med 370(15):1432-1439, 2014.
Castells MC, Hornick JL, Akin C: Anaphylaxis after Hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 3(3):310-355, 2015.
Ertoy Karagol HI, Bakirtas A, Yilmaz O, et al: Long-term follow-up of re-sting reactions in children with moderate to severe venom hypersensitivity, Eur J Pediatr 174(7):891-896, 2015.
Golden DB: Large local reactions to insect stings, J Allergy Clin Immunol Pract 3(3):331-334, 2015.
Golden DB, Demain J, Freeman T, et al: Stinging insect hypersensitivity: a practice parameter update 2016, Ann Allergy Asthma Immunol 118(1):28-54, 2017.
Pacak K: Anaphylaxis and insect stings and bites, JAMA 318(1):86-87, 2017.
Stoevesandt J, Hosp C, Kerstan A, et al: Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective, Ann Allergy Asthma Immunol 114(5):411-416, 2015.
Tankersley MS, Ledford DK: Stinging insect allergy: state of the art 2015, J Allergy Clin Immunol Pract 3(3):315-322, 2015.
Bielory BP, Shah SP, O’Brien TP, et al: Emerging therapeutics for ocular surface disease, Curr Opin Allergy Clin Immunol 16(5):477–486, 2016.
Castillo M, Scott NW, Mustafa MZ, et al: Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis, Cochrane Database Syst Rev (6):CD009566, 2015.
Chen JJ, Applebaum DS, Sun GS, et al: Atopic keratoconjunctivitis: a review, J Am Acad Dermatol 70(3):569–575, 2014.
Esposito S, Fior G, Mori A, et al: An update on the therapeutic approach to vernal keratoconjunctivitis, Paediatr Drugs 18(5):347–355, 2016.
Gomes PJ: Trends in prevalence and treatment of ocular allergy, Curr Opin Allergy Clin Immunol 14(5):451–456, 2014.
Jutel M, Agache I, Bonini S, et al: International consensus on allergy immunotherapy, J Allergy Clin Immunol 136(3):556–568, 2015.
Shaker M, Salcone E: An update on ocular allergy, Curr Opin Allergy Clin Immunol 16(5):505–510, 2016.
Barniol C, Dehours E, Mallet J, et al: Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: a randomized double-blind clinical trial, Ann EmergMed 71(1):125–131, 2018.
Boyden SE, Desai A, Cruse G, et al: Vibratory urticaria associated with a missense variant in ADGRE2, N Engl J Med 374(7):656–663, 2016.
Farkas H, Martinez-Saguer I, Bork K, et al: International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency, Allergy 72:300–313, 2017.
Frank MM: Hereditary angioedema: the clinical syndrome and its management in the United States, Immunol Allergy Clin North Am 26:653–668, 2006.
Frank MM, Zuraw B, Banerji A, et al: Management of children with hereditary angioedema due to C1 inhibitor deficiency, Pediatrics 138(5):e20160575, 2016.
Hawkey S, Ghaffar SA: Glove-related hand urticaria: an increasing occupational problem amongst health care workers, Br J Dermatol 174(5):1137–1140, 2016.
Kanazawa N: Hereditary disorders presenting with urticaria, Immunol Allergy Clin North Am 34:169–179, 2014.
Kennedy JL, Stallings AP, Platts-Mills TA, et al: Galactose-alpha-1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children, Pediatrics 131(5): e1545–e1552, 2013.
Longhurst H, Cicardi M, Craig T, et al: Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor, N Engl J Med 376(12):1131–1140, 2017.
Maurer M, Rosen K, Hsieh HJ, et al: Omalizumab for the treatment of chronic idiopathic or spontaneous urticarial, N Engl J Med 368(10):924–934, 2013.
The Medical Letter: allergic rhinitis, Med Lett Drugs Ther 59(1520):71–80, 2017.
The Medical Letter: omalizumab (Xolair) for chronic urticarial, Med Lett Drugs Ther 55(1417):43–44, 2013.
Ombrello MJ, Remmers EF, Sun G, et al: Cold urticarial, immunodeficiency, and autoimmunity related to PLCG2 deletions, N Engl J Med 366(4):330–338, 2012.
Peroni A, Colato C, Zanoni G, Girolomoni G: Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria, J Am Acad Dermatol 62(4):557–570, 2009.
Powell RJ, Du Toit GL, Siddique N, et al: BSACI guidelines for the management of chronic urticaria and angio-oedema, Clin Exp Allergy 37:631–650, 2007.
Riedl MA: Update on the acute treatment of hereditary angioedema, Allergy Asthma Proc 32:11–16, 2011.
Saini S, Rosen KE, Hsieh HJ, et al: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistimine-refractory chronic idiopathic urticarial, J Allergy Clin Immunol 128(3):567–573, 2011.
Youseff MJ, Chiu YE: Eczema and urticaria as manifestations of undiagnosed and rare diseases, Pediatr Clin North Am 64:39–56, 2017.
Zitelli KB, Cordoro KM: Evidence-based evaluation and management of chronic urticaria in children, Pediatr Dermatol 28:629–639, 2011.
Zuberbier T: A summary of the new international EAACI/GA(2)LEN/EDF/WAO guidelines in urticaria, World Allergy Organ J 5:S1–S5, 2012.
Zuraw BL: Clinical practice. Hereditary angioedema, N Engl J Med 359:1027–1036, 2008.
Akin C: Mast cell activation syndromes presenting as anaphylaxis, Immunol Allergy Clin North Am 35(2):277-285, 2015.
Alqurashi W, Stiell I, Chan K, et al: Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis, Ann Allergy Asthma Immunol 115(3): 217-223.e2, 2015.
Boyce JA, Assa'ad A, Burks AW, et al: Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel, J Allergy Clin Immunol 126:S1-S58, 2010.
Brown JC, Tuuri RE, Akhter S, et al: Lacerations and embedded needles caused by epinephrine autoinjector use in children, Ann Emerg Med 67(3) :307-315, 2017.
Dahdah L, Ceccarelli S, Amendola S, et al: IgE immunoadsorption knocks down the risk of food-related anaphylaxis, Pediatrics 136(6):e1617-e1620, 2015.
Dhami S, Panesar SS, Roberts G, et al: Management of anaphylaxis: a systematic review, Allergy 69(2):168-175, 2014.
Farbman KS, Michelson KA: Anaphylaxis in children, Curr Opin Pediatr 28:294-297, 2016.
Fellinger C, Hemmer W, Wohrl S, et al: Clinical characteristics and risk profile of patients with elevated baseline serum tryptase, Allergol Immunopathol (Madr) 42(6):544-552, 2014.
Fenny N, Grammer LC: Idiopathic anaphylaxis, Immunol Allergy Clin North Am 35:349-362, 2015.
Gonzalez-Quintela A, Vizcaino L, Gude F, et al: Factors influencing serum total tryptase concentrations in a general adult population, Clin Chem Lad Med 48(5):701-706, 2010.
Kennedy JL, Stallings AP, Platts-Mills TAE, et al: Galactose-a-1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children, Pediatrics 131(5):e1545-e1552, 2013.
Koplin JJ, Martin PE, Allen KJ: An update on epidemiology of anaphylaxis in children and adults, Curr Opin Allergy Clin Immunol 11(5):492-496, 2011.
Lee S, Hess EP, Lohse C, et al: Trends, characteristics, and incidence of anaphylaxis in 2001-2010: a population-based study, J Allergy Clin Immunol 139(1):182-188, 2017.
Lieberman P, Nicklas RA, Randolph C, et al: Anaphylaxis—a practice parameter update 2015, Ann Allergy Asthma Immunol 115(5):341-384, 2015.
Loprinzi Brauer CE, Motosue MS, Li JT, et al: Prospective validation of the NIAID/ FAAN criteria for emergency department diagnosis of anaphylaxis, J Allergy Clin Immunol Pract 4(6):1220-1226, 2016.
Muraro A, Roberts G, Worm M, et al: Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology, Allergy 69(8):1026-1045, 2014.
O'Keefe A, Clarke A, St Pierre Y, et al: The risk of recurrent anaphylaxis, J Pediatr 180:217-221, 2017.
Russell S, Monroe K, Losek JD: Anaphylaxis management in the pediatric emergency department, Pediatr Emerg Care 26(2):71-76, 2010.
Sicherer SH, Simons FE: Epinephrine for first-aid management of anaphylaxis, Pediatrics 139(3):e20164006, 2017.
Simons FE, Ardusso LR, Bild MB, et al: International consensus on (ICON) anaphylaxis, World Allergy Organ J 7(1):9, 2014.
Simons FE, Ebisawa M, Sanchez-Borges M, et al: 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines, World Allergy Organ J 8(1):32, 2015.
Wang J, Sicherer SH: Guidance on completing a written allergy and anaphylaxis emergency plan, Pediatrics 139(3):e20164005, 2017.
American Academy of Pediatrics, Pickering LK, editors: Red book: 2012 report of the committee on infectious diseases, ed 29, Elk Grove Village, IL, 2012, American Academy of Pediatrics, pp 63–66.
Bonds RS, Kelly BC: Severe serum sickness after H1N1 influenza vaccination, Am J Med Sci 345:412–413, 2013.
Chiong FJ, Loewenthal M, Boyle M, Attia J: Serum sickness-like reaction after influenza vaccination, BMJ Case Rep 16:2015.
Couvrat-Desvergnes G, Salama A, Le Berre L, et al: Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival, J Clin Invest 125:4655–4665, 2015.
Hansel TT, Kropshofer H, Singer T, et al: The safety and side effects of monoclonal antibodies, Nat Rev Drug Discov 9:325, 2010.
Kojis FG: Serum sickness and anaphylaxis: analysis of cases of 6,211 patients treated with horse serum for various infections, Am J Dis Child 64:93–143, 1942.
Lawley TJ, Bielory L, Gascon P, et al: A prospective clinical and immunological analysis of patients with serum sickness, N Engl J Med 311:1407–1413, 1984.
Le Guenno G, Ruivard M, Charra L, et al: Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura, Intern Med J 41(2):202–205, 2011.
Schaeffer TH, Khatri V, Reifler LM, et al: Incidence of immediate hypersensitivity reactions and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis, Acad Emerg Med 19(2):121–131, 2012.
Abrams EM, Greenhawt M, Fleischer DM, Chan ES: Early solid food introduction: role in food allergy prevention and implications for breastfeeding, J Pediatr 184:13–18, 2017.
Akuete K, Guffey D, Israelsen RB, et al: Multicenter prevalence of anaphylaxis in clinic-based oral food challenges, Ann Allergy Asthma Immunol 119(4):339–342, 2017.
American Academy of Pediatrics Policy Statement: Committee on Infectious Disease: recommendations for prevention and control of influenza in children, 2016–2017, Pediatrics 138(4):2016.
Boyce JA, Assa'ad A, Burks AW, et al: Guideline for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel, J Allergy Clin Immunol 126(6):S1–S58, 2010.
Burks AW, Jones SM, Boyce JA, et al: NIAID-sponsored 2010 guidelines for managing food allergy: applications in the pediatric population, Pediatrics 128:955–965, 2011.
Burks AW, Jones SM, Wood RA, et al: Oral immunotherapy for treatment of egg allergy in children, N Engl J Med 367:233–243, 2012.
Burks AW, Wood RA, Jones SJ, et al: Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial, J Clin Allergy Immunol 135(5):1240–1248, 2015.
Couch C, Franxman T, Greenhawt M: Characteristics of tree nut challenges in tree nut allergic and tree nut sensitized individuals, Ann Allergy Asthma Immunol 118:591–596, 2017.
Du Toit G, Roberts G, Sayre PH, et al: Randomized trial of peanut consumption in infants at risk for peanut allergy, N Engl J Med 372(9):803–813, 2015.
Du Toit G, Sayre PH, Roberts G, et al: Effect of avoidance on peanut allergy after early peanut consumption, N Engl J Med 374(15):1435–1443, 2016.
Fleischer DM, Burks AW, Vickery BP, et al: Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial, J Allergy Clin Immunol 131:119–127, 2013.
Fleischer DM, Sicherer S, Greenhawt M, et al: Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants, Pediatrics 136(3):600–604, 2015.
Foolad N, Brezinski EA, Chase EP, et al: Effect of nutrient supplementation on atopic dermatitis in children, JAMA Dermatol 149:350–355, 2013.
Gottlieb S, US Food and Drug Administration: Statement on a new qualified health claim advising that early introduction of peanuts to certain high-risk infants may reduce risk of peanut allergy, https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm575008.htm.
Greer FR, Sicherer SH, Burks AW: Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas, Pediatrics 121:183–191, 2008.
Grohskopf LA, Sokolow LZ, Broder KR, et al: Prevention and control of seasonal influenza with vaccines, MMWR Recomm Rep 65(5):1–54, 2016.
Horimukai K, Morita K, Narita M, et al: Application of moisturizer to neonates prevents development of atopic dermatitis, J Allergy Clin Immunol 134(4):824–830, 2014.
Huang F, Chawla K, Jarvinen KM, et al: Anaphylaxis in a New York City pediatric emergency department: triggers, treatments, and outcomes, J Allergy Clin Immunol 129:162–168, 2011.
Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al: The safety and efficacy of sublingual and oral immunotherapy for milk allergy, J Allergy Clin Immunol 129:448–455, 2012.
Kim EH, Burks W: Managing food allergy in childhood, Curr Opin Pediatr 24:615–620, 2012.
Kim JS, Nowak-W?grzyn A, Sicherer SH, et al: Dietary baked milk accelerates the resolution of cow's milk allergy in children, J Allergy Clin Immunol 128:125–131, 2011.
Klemans RJB, Otte D, Knol M, et al: The diagnostic value of specific IgE to Ara h 2 to predict peanut allergy in children is comparable to a validated and updated diagnostic prediction model, J Allergy Clin Immunol 131(1):157–163, 2013.
Lack G: Update on risk factors for food allergy, J Allergy Clin Immunol 129:1187–1197, 2012.
Leonard SA, Nowak-W?grzyn A: Food protein-induced entercolitis syndrome, Pediatr Clin North Am 62:1463–1477, 2015.
Leonard SA, Sampson HA, Sicherer SH, et al: Dietary baked egg accelerates resolution of egg allergy in children, J Allergy Clin Immunol 130:473–480, 2012.
Lerodiakonou D, Garcia-Larsen V, Logan A, et al: Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis, JAMA 316(11):1181–1192, 2016.
Li J, Maggadottir SM, Hakonarson H: Are genetic tests informative in predicting food allergy? Curr Opin Allergy Clin Immunol 16(3):257–264, 2016.
Lin J, Bruni FM, Fu Z, et al: A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay, J Allergy Clin Immunol 129:1321–1328, 2012.
Lowe AJ, Hosking CS, Bennett CM, et al: Effect of a partially hydrolyzed whey infant formula at weaning on risk of allergic disease in high-risk children: a randomized controlled trial, J Allergy Clin Immunol 128(2):360–365, 2011.
Natsume O, Kabashima S, Nakazato J, et al: Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomized, double-blind, placebo-controlled trial, Lancet 389:276–286, 2017.
Nowak-W?grzyn A, Sampson HA: Future therapies for food allergies, J Allergy Clin Immunol 127:558–573, 2011.
Nwaru BI, Erkkola M, Ahonen S, et al: Age at introduction of solid foods during the first year and allergic sensitization at age 5 years, Pediatrics 125:50–59, 2010.
Nwaru BI, Takkinen HM, Niemela O, et al: Timing of infant feeding in relation to childhood asthma and allergic diseases, J Allergy Clin Immunol 131:78–86, 2013.
Osborn DA, Sinn JKH: Prebiotics in infants for prevention of allergy (review), Cochrane Database Syst Rev (3):CD006474, 2013.
Palmer DJ, Sullivan TR, Gold MS, et al: Randomized controlled trial of early regular egg intake to prevent egg allergy, J Allergy Clin Immunol 139(5):1600–1607, 2017.
Perkin MR, Logan K, Tseng A, et al: Randomized trial of introduction of allergenic foods in breast-fed infants, N Engl J Med 374(18):1733–1743, 2016.
Roberts G: Another step towards prevention of food allergy, Lancet 389:230–231, 2017.
Roduit C, Frei R, Depner M, et al: Increased food diversity in the first year of life is inversely associated with allergic diseases, J Allergy Clin Immunol 133:1056–1064, 2014.
Rudders SA, Banerji A, Clark S, et al: Age-related differences in the clinical presentation of food-induced anaphylaxis, J Pediatr 158:326–328, 2011.
Sackeyflo A, Senthinathan A, Kandaswamy P, et al: Diagnosis and assessment of food allergy in children and young people: summary of NICE guidance, BMJ 342:544–546, 2011.
Sampson HA, Aceves S, Bock SA, et al: Food allergy: a practice parameter update — 2014, J Allergy Clin Immunol 134: 1025.e1–1025.e43, 2014.
Sampson HA: Peanut oral immunotherapy: is it ready for clinical practice? J Allergy Clin Immunol Pract 1:15–21, 2013.
Sansotta N, Placentini GL, Mazzel F, et al: Timing of introduction of solid food and risk of allergic disease development: understanding the evidence, Allergol Immunopathol (Madr) 41(5):337–345, 2013.
Savage J, Sicherer S, Wood R: The natural history of food allergy, J Allergy Clin Immunol Pract 4(2):196–203, 2016.
Schneider Chafen JJ, Newberry SJ, Riedl MA, et al: Diagnosing and managing common food allergies, JAMA 303(18):1848–1856, 2010.
Sicherer SH, Mahr T: Section on Allergy and Immunology: clinical report — management of food allergy in the school setting, Pediatrics 126:1232–1239, 2010.
Sicherer SH, Vargas PA, Groetch ME, et al: Development and validation of educational materials for food allergy, J Pediatr 160:651–656, 2012.
Simpson EL, Chalmers JR, Hanifin JM, et al: Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention, J Allergy Clin Immunol 134(4):818–823, 2014.
Spergel JM: Natural history of cow's milk allergy, J Allergy Clin Immunol 131:813–814, 2013.
Togias A, Cooper S, Acebal M, et al: Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel, J Allergy Clin Immunol 139(1):29–44, 2017.
Wood RA, Kim JS, Lindblad R, et al: A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy, J Allergy Clin Immunol 137(4):1103–1110, 2016.
Wood RA, Sicherer SH, Vickery BP, et al: The natural history of milk allergy in an observational cohort, J Allergy Clin Immunol 131:805–812, 2013.
Blumenthal KG, Youngster I, Rabideau DJ, et al: Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics, J Allergy Clin Immunol 136(5):1288–1294, 2015.
Chung WH, Wang CW, Dao RL: Severe cutaneous adverse drug reactions, J Dermatol 43(7):758–766, 2016.
Galvao VR, Castells MC: Hypersensitivity to biological agents: updated diagnosis, management, and treatment, J Allergy Clin Immunol Pract 3(2):175–185, 2015.
Gomes ER, Brockow K, Kuyucu S, et al: Drug hypersensitivity in children: report from the Pediatric Task Force of the EAACI Drug Allergy Interest Group, Allergy 71(2):149–161, 2016.
Jacquier J, Chik CL, Senior PA: A practical, clinical approach to the assessment and management of suspected insulin allergy, Diabet Med 30(8):977–985, 2013.
Khan DA: Pharmacogenomics and adverse drug reactions: primetime and not ready for primetime tests, J Allergy Clin Immunol 138(4):943–955, 2016.
Pyle RC, Butterfield JH, Volcheck GW, et al: Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction, J Allergy Clin Immunol Pract 2(1):52–58, 2014.
Romano A, Caubet JC: Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis, J Allergy Clin Immunol Pract 2(1):3–12, 2014.
Rosado Ingelmo A, Dona Diaz I, Cabanas Moreno R, et al: Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media, J Investig Allergol Clin Immunol 26(3):144–155, 2016.
Sousa-Pinto B, Pinto-Ramos J, Correia C, et al: Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01, J Allergy Clin Immunol 163(4):1092–1094, 2015.
Trubiano JA, Adkinson NF, Phillips EJ: Penicillin allergy is not necessarily forever, JAMA 318(1):82–83, 2017.
Volcheck GW, Mertes PM: Local and general anesthetics immediate hypersensitivity reactions, Immunol Allergy Clin North Am 34(3):525–546, 2014.
Vyles D, Adams J, Chiu A, et al: Allergy testing in children with low-risk penicillin allergy symptoms, Pediatrics 140(2): e20170471, 2017.
Walters KM, Woessner KM: An overview of nonsteroidal anti-inflammatory drug reactions, Immunol Allergy Clin North Am 36(4):625–641, 2016.
Wheatley LM, Plaut M, Schwaninger JM, et al: Report from the national institute of allergy and infectious diseases workshop on drug allergy, J Allergy Clin Immunol 136(2):262–271, 2015.
Aiuti A, Biasco L, Scaramuzza S, et al: Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, Science 341(6148):1233151, 2013.
Chang DR, Toh J, de Vos G, Gavrilova T: Early diagnosis in dedicator of cytokinesis 8 (DOCK8) deficiency, J Pediatr 179:33–35, 2016.
Dobbs K, Dominguez Conde C, Zhang SY, et al: Inherited DOCK2 deficiency in patients with early-onset invasive infections, N Engl J Med 372(25):2409–2422, 2015.
Hacein-Bey Abina S, Gaspar B, Blondeau J, et al: Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, JAMA 313(15):1550–1562, 2015.
Hagl B, Heinz V, Schlesinger A, et al: Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children, Pediatr Allergy Immunol 27(2):177–184, 2016.
Jouhadi Z, Khadir K, Ailal F, et al: Ten-year follow-up of a DOCK8-deficient child with features of systemic lupus erythematosus, Pediatrics 134:e1458–e1463, 2014.
Notarangelo LD: Functional T cell immunodeficiencies (with T cells present), Annu Rev Immunol 31:195–225, 2013.
Rider NL, Morton DH, Puffenberger E, et al: Immunologic and clinical features of 25 Amish patients with RMRP 70 A?G cartilage hair hypoplasia, Clin Immunol 131(1):119–128, 2009.
Uygungil B, Minka E, Crawford T, Lederman H:
Safety of live viral vaccines and retrospective review of immunologic status of 329 patients with ataxia telangiectasia, J Clin Immunol 32:366, 2012.
Yang L, Fliegauf M, Grimbacher B: Hyper-IgE syndromes: reviewing PGM3 deficiency, Curr Opin Pediatr 26:697–703, 2014.
Picard C, Al-Herz W, Bousfiha A, et al: Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015, J Clin Immunol 35(8):696–726, 2015.
Prando C, Samarina A, Bustamante J, et al: Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds, Medicine (Baltimore) 92:109–122, 2013.
Wu U, Holland SM: Host susceptibility to non-tuberculous mycobacterial infections, Lancet Infect Dis 15(8):968–980, 2015.
Barzaghi F, Passerini L, Bacchetta R: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity, Front Immunol 3:1–25, 2012.
Chandesris MO, Melki I, Natividad A, et al: Autosomal dominant STAT3 deficiency and hyper-IgE syndrome, Medicine (Baltimore) 91:e1–e19, 2012.
Coulter TI, Chandra A, Bacon CM, et al: Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study, J Allergy Clin Immunol 139(2):597–606.e4, 2017.
Felgentreff K, Perez-Becker R, Speckmann C, et al: clinical and immunological manifestations of patients with atypical severe combined immunodeficiency, Clin Immunol 141:73–82, 2011.
Gamez-Diaz L, August D, Stepensky P, et al: The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency, J Allergy Clin Immunol 137(1):223–230, 2016.
Haverkamp MH, van de Vosse E, van Dissel JT: Nontuberculous mycobacterial infections in children with inborn errors of the immune system, J Infect 68:S134–S150, 2014.
Lo B, Zhang K, Lu W, et al: Autoimmune disease: patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy, Science 349(6246):436–440, 2015.
Nieves DS, Phipps RP, Pollock SJ, et al: Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, Arch Dermatol 140:466–472, 2004.
Oliveria JB: The expanding spectrum of the autoimmune lymphoproliferative syndromes, Curr Opin Pediatr 25:722–729, 2013.
Dinauer MC, Coates TD: Disorders of phagocyte function. In Hoffman R, Benz EJ, Silberstein LE, et al, editors: Hematology: basic principles and practice, Philadelphia, 2012, Saunders, pp 655–674.
Flannagan RS, Jaumouill? V, Grinstein S: The cell biology of phagocytosis, Annu Rev Pathol 7:61–98, 2012.
Klebanoff SJ, Kettle AJ, Rosen H, et al: Myeloperoxidase: a front-line defender against phagocytosed microorganisms, J Leukoc Biol 93(2):185–198, 2013.
Kolaczkowska E, Kubes P: Neutrophil recruitment and function in health and inflammation, Nat Rev Immunol 13(3):159–175, 2013.
Ortega-Gomez A, Perretti M, Soehnlein O: Resolution of inflammation: an integrated view, EMBO Mol Med 5(5):661–674, 2013.
Schmidt S, Moser M, Sperandio M: The molecular basis of leukocyte recruitment and its deficiencies, Mol Immunol 55(1):49–58, 2013.
Timur CI, Lurincz AM, Ligeti E: Changing world of neutrophils, Pflugers Arch 465(11):1521–1533, 2013.
Emile J-F, Oussama A, Fraitag S, et al: Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood 127:2672–2681, 2016.
Serhan CN: Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms, EMBO J 31:1273–1288, 2017.
Tam VC, Aderem A: Macrophage activation as an effector mechanism for cell-mediated immunity, J Immunol 193:3183–3184, 2014. Introducing reproduced pillar articles:
Mackaness GB: J Exp Med 116:381–406, 1962 and J Exp Med 120:105–120, 1964.
Underwood E: Wired: Beth Stevens and her network of collaborators are showing how immune cells sculpt connections in the brain, Science 353:762–785, 2016.
Villani A-C, Satija R, Reynolds G, et al: Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors, Science 356:283, 2017.
Wynn TA, Chawla A, Pollard JW: Macrophage biology in development, homeostasis and disease, Nature 496:445–455, 2013.
Yang L, Zhang Y: Tumor-associated macrophages: from basic research to clinical application, J Hematol Oncol 10:58–69, 2017.
Bochner BS, Book W, Busse WW, et al: Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD), J Allergy Clin Immunol 130(3):587–596, 2012.
Curtis C, Ogbogu PU: Evaluation and differential diagnosis of persistent marked eosinophilia, Immunol Allergy Clin North Am 35(3):387–402, 2015.
Furuta GT, Katzka DA: Eosinophilic esophagitis, N Engl J Med 373(17):1640–1648, 2015.
Gotlib J: World Health Organization–defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management, Am J Hematol 90(11):1077–1089, 2015.
Klion AD: How I treat hypereosinophilic syndromes, Blood 126(9):1069–1077, 2015.
Legraand F, Klion AD: Biologic therapies targeting eosinophils: current status and future prospects, J Allergy Clin Immunol Pract 3(2):167–174, 2015.
Rosenberg HF, Dyer KD, Foster PS: Eosinophils: changing perspectives in health and disease, Nat Rev Immunol 13(1):9–22, 2013.
Roufosse F, Weller PF: Practical approach to the patient with hypereosinophilia, J Allergy Clin Immunol 126(1):39–44, 2010.
Simon HU, Rothenberg ME, Bocher BS, et al: Refining the definition of hypereosinophilic syndrome, J Allergy Clin Immunol 126:45–49, 2010.
Valent P, Klion AD, Horny HP, et al: Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes, J Allergy Clin Immunol 130(3):607–612, 2012.
Aiuti A, Bacchetta R, Seger R, et al: Gene therapy for primary immunodeficiencies. Part 2, Curr Opin Immunol 24(5):585–591, 2012.
Baghdasraian E, Coates TD, Harb R, et al: Serologic assessment for inflammatory bowel disease in patients with chronic granulomatous disease, Pediatr Allergy Immunol Pulmonol 23(4):261–263, 2010.
Dinauer MC, Coates TD: Disorders of phagocyte function. In Hoffman R, Benz EJ, Silberstein LE, et al, editors: Hematology: basic principles and practice, Philadelphia, 2012, Saunders, pp 655–674.
Kang EM, Marciano BE, DeRavin S, et al: Chronic granulomatous disease: overview and hematopoietic stem cell transplantation, J Allergy Clin Immunol 127(6):1319–1326, quiz 1327–1328, 2011.
Moutsopoulos NM, Zerbe CS, Wild T, et al: Interleukin-12 and interleukin-23 blockade in leucocyte adhesion deficiency type 1, N Engl J Med 376(12):1141–1146, 2017.
Parekh C, Hofstra T, Church JA, et al: Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease, Pediatr Blood Cancer 56(3):460–462, 2011.
Rieber N, Hector A, Kuijpers T, et al: Current concepts of hyperinflammation in chronic granulomatous disease, Clin Dev Immunol 2012:252460, 2012.
Andersohn F, Konzen C, Garbe E: Systematic review: agranulocytosis induced by nonchemotherapy drugs, Ann Intern Med 146:657–665, 2007.
Boztug K, Klein C: Genetics and pathophysiology of severe congenital neutropenia syndromes unrelated to neutrophil elastase, Hematol Oncol Clin North Am 27:43–60, 2013.
Boztug K, Rosenberg PS, Dorda M, et al: Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia, J Pediatr 160:679–683, 2012.
Bruin M, Dassen A, Pajkrt D, et al: Primary autoimmune neutropenia in children: a study of neutrophil antibodies and clinical course, Vox Sang 88:52–59, 2005.
Clay ME, Schuller RM, Bachowski GJ: Granulocyte serology: current concepts and clinical significance, Immunohematology 26:11–21, 2010.
Fioredda F, Calvillo M, Bonanomi S, et al: Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica), Pediatr Blood Cancer 57:10–17, 2011.
Hauk F, Klein C: Pathogenic mechanisms and clinical implications of congenital neutropenia syndromes, Curr Opin Allergy Clin Immunol 13:596–606, 2013.
Husain EH, Mullah-Ali A, Al-Sharidah S, et al: infectious etiologies of transient neutropenia in previously healthy children, Pediatr Infect Dis J 31:575–577, 2012.
Jacobs ZD, Guajardo JR, Anderson KM: XLA-associated neutropenia treatment: a case report and review of the literature, J Pediatr Hematol Oncol 30(8):631–634, 2008.
Makaryan V, Zeidler C, Bolyard AA, et al: The diversity of mutations and clinical outcomes for ELANE-associated neutropenia, Curr Opin Hematol 22(1):3–11, 2015.
Newburger PE, Dale DC: Evaluation and management of patients with isolated neutropenia, Semin Hematol 50(3):198–206, 2013.
Rosenberg PS, Zeidler C, Bolyard AA, et al: Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy, Br J Haematol 150:196–199, 2010.
Cerny J, Rosmarin AG: Why does my patient have leukocytosis? Hematol Oncol Clin North Am 26:303–319, 2012.
Summers C, Rankin SM, Condliffe AM, et al: Neutrophil kinetics in health and disease, Trends Immunol 31:318–324, 2010.
Hess C, Kemper C: Complement-mediated regulation of metabolism and basic cellular processes, Immunity 45:240–254, 2016.
Kolev M, Kemper C: Keeping it all going: complement meets metabolism, Front Immunol 8:1–18, 2017.
Kouser L, Madhukaran SP, Shastri A, et al: Emerging and novel functions of complement protein C1q, Front Immunol 6:317–335, 2015.
Leslie M: The new view of complement, Science 337:1034–1037, 2012.
Liszewski MK, Atkinson JP: Complement regulators in human disease: lessons from modern genetics, J Intern Med 277:294–305, 2015.
Underwood E: Neuroimmunology: wired: Beth Stevens and her network of collaborators are showing how immune cells sculpt connections in the brain, Science 353:762–765, 2016.
Varela JC, Tomlinson S: Complement: an overview for the clinician, Hematol Oncol Clin North Am 29:409–427, 2015.
Bajic G, Degn SE, Thiel S, Andersen GR: Complement activation, regulation, and molecular basis for complement-related diseases, EMBO J 34:2735–2757, 2015.
Giclas PC: Evaluation of complement activation and its clinical relevance. In Detrick B, Hamilton RG, Folds JD, editors: Manual of molecular and clinical laboratory immunology, ed 7, Washington, DC, 2006, ASM Press, pp 115–117.
Botto M, Kirschfink M, Macor P, et al: Complement in human diseases: lessons from complement deficiencies, Mol Immunol 46:2774–2783, 2009.
Manian FA, Alame D: Case 11-2015: A 28-year-old woman with headache, fever, and a rash, N Engl J Med 372:1454–1462, 2015.
Ricklin D, Lambris JD: Complement in immune and inflammatory disorders: pathophysiological mechanisms, J Immunol 190:3831–3838, 2013.
Sfyroera G, Ricklin D, Reis ES, et al: Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity, J Immunol 194:3305–3316, 2015.
Slade C, Bosco J, Unglik G, et al: Deficiency in complement factor B, N Engl J Med 369:1667–1669, 2013.
Tebruegge M, Curtis N: Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis, Clin Microbiol Rev 21:519–537, 2008.
Banerji A, Riedl MA, Bernstein JA, et al: Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks, JAMA 320(20):2108–2121, 2018.
Martinez-Saguer I, Farkas H: Erythema marginatum as an early symptom of hereditary angioedema: case report of 2 newborns, Pediatrics 137(2):e20152411, 2017.
Sekar A, Bialas AE, De Rivera H, et al: Schizophrenia risk from complex variation of complement component 4, Nature 530:177–183, 2016.
Zuraw BL, Christiansen SC: HAE pathophysiology and underlying mechanisms, Clin Rev Allergy Immunol 51:216–229, 2016.
Banerji A, Busse P, Shennak M, et al: Inhibiting plasma kallikrein for hereditary angioedema prophylaxis, N Engl J Med 376:717–728, 2017.
Bosmann M, Ward PA: The inflammatory response in sepsis, Trends Immunol 34:129–136, 2012.
Sethi S, Sullivan A, Smith RJ: C4 dense-deposit disease, N Engl J Med 370:784–786, 2014.
Wang RH, Phillips G Jr, Medof ME, et al: Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients, J Clin Invest 92:1326–1355, 1993.
Wood JH, Partrick DA, Johnston RB Jr: The inflammatory response to injury in children, Curr Opin Pediatr 22:315–320, 2010.
Banerji A, Busse P, Shennak M, et al: Inhibiting plasma kallikrein for hereditary angioedema prophylaxis, N Engl J Med 376:717–728, 2017.
Frank MM, Zuraw B, Banerji A, et al: Management of children with hereditary angioedema due to C1 inhibitor deficiency, Pediatrics 138:e20160575, 2017.
Legendre CM, Licht C, Muus P, et al: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med 368:2169–2181, 2013.
Longhurst H, Cicardi M, Craig T, et al: Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor, N Engl J Med 376:1131–1140, 2017.
Lumry W, Manning ME, Hurewitz DS, et al: Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children, J Pediatr 162:1017–1022, 2013.
MacGinnitie AJ, Davis-Lorton M, Stolz LE, et al: Use of ecallantide in pediatric hereditary angioedema, Pediatrics 132:381–382, e490–e497, 2013.
Zuraw BL, Bernstein JA, Lang DM, et al: A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema, J Allergy Clin Immunol 131:1491–1518, 2013.
Chen Y-B, Wang T, Hemmer MT, et al: GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes, Bone Marrow Transplant 52(3):400–408, 2016.
Faridi RM, Kemp TJ, Dharmani-Khan P, et al: Donor-recipient matching for KIR genotypes reduces chronic GVHD and missing inhibitory KIR ligands protect against relapse after myeloablative, HLA matched hematopoietic cell transplantation, PLoS ONE 11(6):e0158242, 2016.
Gragert L, Eapen M, Williams E, et al: HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry, N Engl J Med 371:339–348, 2014.
Kurtzberg J, Prasad VK, Carter SL, et al: COBLT Steering Committee. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies, Blood 112:4318–4327, 2008.
Li Pira G, Di Cecca S, Montnari M, et al: Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies, and perspectives, Blood Rev 30(4):297–307, 2016.
Oevermann L, Michaelis SU, Mezger M, et al: KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL, Blood 124(17):2744–2747, 2014.
Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S: Clinical relevance of natural killer cells following hematopoietic stem cell transplantation, J Cancer 4(1):25–35, 2013.
Vacca P, Montaldo E, Croxatto D, et al: NK cells and other innate lymphoid cells in hematopoietic stem cell transplantation, Front Immunol 18(7):188, 2016.
Wagner JE, Eapen M, Carter S, et al: One-unit versus two-unit cord-blood transplantation for hematologic cancers, N Engl J Med 371:1685–1694, 2014.
Chen Y-B, Wang T, Hemmer MT, et al: GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes, Bone Marrow Transplant 52(3):400–408, 2016.
Faridi RM, Kemp TJ, Dharmani-Khan P, et al: Donor-recipient matching for KIR genotypes reduces chronic GVHD and missing inhibitory KIR ligands protect against relapse after myeloablative, HLA matched hematopoietic cell transplantation, PLoS ONE 11(6):e0158242, 2016.
Gragert L, Eapen M, Williams E, et al: HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry, N Engl J Med 371:339–348, 2014.
Kurtzberg J, Prasad VK, Carter SL, et al: COBLT Steering Committee. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies, Blood 112:4318–4327, 2008.
Li Pira G, Di Cecca S, Montnari M, et al: Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies, and perspectives, Blood Rev 30(4):297–307, 2016.
Oevermann L, Michaelis SU, Mezger M, et al: KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL, Blood 124(17):2744–2747, 2014.
Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S: Clinical relevance of natural killer cells following hematopoietic stem cell transplantation, J Cancer 4(1):25–35, 2013.
Vacca P, Montaldo E, Croxatto D, et al: NK cells and other innate lymphoid cells in hematopoietic stem cell transplantation, Front Immunol 18(7):188, 2016.
Wagner JE, Eapen M, Carter S, et al: One-unit versus two-unit cord-blood transplantation for hematologic cancers, N Engl J Med 371:1685–1694, 2014.
Ball LM, Bernardo ME, Roelofs H, et al: Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease, Br J Haematol 163:501–509, 2013.
Bolanos-Meade J, Logan BR, Alousi AM, et al: Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802, Blood 124(22):3221–3227, 2014.
Corbaciaglu S, Cesaro S, Faraci M, et al: Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haematopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial, Lancet 379:1301–1309, 2012.
Harris AC, Young R, Devine S, et al: International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium, Biol Blood Marrow Transplant 22:4–10, 2016.
Holtan SG, Macmillan ML: A risk-adapted approach to acute GVHD treatment: are we there yet?, Bone Marrow Transplant 51(2):172–175, 2016.
Jagasia MH, Greinix HT, Arora M, et al: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. I. The 2014 Diagnosis and Staging Working Group Report, Biol Blood Marrow Transplant 21:389–401, 2014.
Koreth SM, Matsuoka K, Kim HT, et al: Interleukin-2 and regulatory T cells in graft-versus-host disease, N Engl J Med 365:2055–2066, 2011.
Malagola M, Cancelli V, Skert C, et al: Extracorporeal photophoresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis of 94 patients on behalf of the Gruppo Italiano Trapianto di Midollo Osseo, Transplantation 100(12):147–155, 2016.
The Medical Letter: Defibrotide (defitelio) for hepatic veno-occlusive disease, Med Lett Drugs Ther 58:120–2016, 1503.
Olsson R, Remberger M, Schaffer M, et al: Graft failure in the modern era of allogeneic hematopoietic SCT, Bone Marrow Transplant 48:537–543, 2013.
Richardson PG, Riches ML, Kernan NA, et al: Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure, Blood 127:1656–1665, 2016.
Skeens MA, McArthur J, Cheifetz IM, et al: High variability in the reported management of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation, Biol Blood Marrow Transplant 22(10):1823–1828, 2016.
Yang J, Cheuk DK, Ha SY, et al: Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic stem cell transplantation, Pediatr Transplant 16(7):771–778, 2012.
Burgos A, Zaoutis TE, Dvorak CC, et al: Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases, Pediatrics 121(5):e1286–e1294, 2008.
Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among hematopoietic sickle cell transplant recipients, MMWR Morb Mortal Wkly Rep 49(RR–10):1–128, 2000.
Chiereghin A, Prete A, Belotti T, et al: Prospective Epstein-Barr virus–related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment, Transpl Infect Dis 18(1):44–54, 2016.
Groll AH, Castagnola E, Cesaro S, et al: Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation, Lancet Oncol 15(8):e327–e340, 2014.
Lehrnbecher T, Robinson P, Fisher B, et al: Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update, J Clin Oncol 35(18):2082–2094, 2017.
Matthes-Martin S, Feuchtinger T, Shaw PJ, et al: European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011), Transpl Infect Dis 14(6):555–563, 2012.
Pappas PG, Kauffman CA, Andes DR, et al: Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America, Clin Infect Dis 62(4):e1–e50, 2016.
Rowe RG, Guo D, Lee M, et al: Cytomegalovirus infection in pediatric hematopoietic stem cell transplantation: risk factors for primary infection and cases of recurrent and late infection at a single center, Biol Blood Marrow Transplant 22(7):1275–1283, 2016.
Slade M, Goldsmith S, Romee R, et al: Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation, Transpl Infect Dis 19(1):2017.
Zaoutis TE, Heydon K, Chu JH, et al: Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000, Pediatrics 117(4):e711–e716, 2006.
Armenian SH, Chemaitilly W, Chen M, et al: National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: the Cardiovascular Disease and Associated Risk Factors Working Group report, Biol Blood Marrow Transplant 23(2):201–210, 2017.
Bonfim C, Ribeiro L, Nichele S, et al: Long-term survival, organ function, and malignancy after hematopoietic stem cell transplantation for Fanconi anemia, Biol Blood Marrow Transplant 22(7):1257–1263, 2016.
Bresters D, Lawitschka A, Cugno C, et al: Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters, Bone Marrow Transplant 51(11):1482–1489, 2016.
Chow EJ, Wong K, Lee SJ, et al: Late cardiovascular complications after hematopoietic cell transplantation, Biol Blood Marrow Transplant 20(6):794–800, 2014.
Chow EJ, Anderson L, Baker KS, et al: Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children’s Oncology Group report, Biol Blood Marrow Transplant 22:782–795, 2016.
Dietz AC, Mehta PA, Vlachos A, et al: Current knowledge and priorities for future research in late effects after hematopoietic cell transplantation for inherited bone marrow failure syndromes: consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant 23(5):726–735, 2017.
Majhail NS, Tao L, Bredeson C, et al: Prevalence of hematopoietic cell transplant survivors in the United States, Biol Blood Marrow Transplant 19(10):1498–1501, 2013.
Pulsipher MA, Skinner R, McDonald GB, et al: First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines, Biol Blood Marrow Transplant 18:334–347, 2012.
Shenoy S, Angelucci E, Arnold SD, et al: Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation, Biol Blood Marrow Transplant 23(4):552–561, 2017.
